🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lu Chen

National Institutes of Health

ORCID: 0000-0001-9708-341X

Also affiliated with City Of Hope National Medical Center, City of Hope, Guangxi Medicinal Botanical Garden, National Center for Advancing Translational Sciences, Beckman Research Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE”.

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood(2022)10.1182/blood.2022015423

N/A

3.0DataRank · unranked

121 citations

Hun Ju Lee, Joycelynne Palmer, Robert Chen, Ni‐Chun Tsai, Lu Chen +18 more

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

The Lancet Haematology(2022)10.1016/s2352-3026(22)00318-0

N/A

1.4DataRank · unranked

41 citations

Lu Chen, Yago Nieto, Leona Holmberg, Patrick B. Johnston, Matthew Mei +20 more

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood(2023)10.1182/blood.2023020485

N/A

1.3DataRank · unranked

40 citations

Lu Chen, James Godfrey, Joo Y. Song, Colt A. Egelston, Sandrine Puverel +18 more

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

The Lancet Haematology(2024)10.1016/s2352-3026(24)00171-6

N/A

0.673DataRank · unranked

20 citations

Jasmine Zain, Kerry J. Savage, Tatyana Feldman, Jonathan E. Brammer, Lu Chen +14 more

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

Haematologica(2023)10.3324/haematol.2023.283002

N/A

0.599DataRank · unranked

19 citations

Matthew Mei, Lu Chen, Joo Y. Song, Victoria Bedell, Elizabeth Budde +13 more

Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma

Leukemia(2022)10.1038/s41375-022-01623-z

N/A

0DataRank · unranked

42 citations

Xuxiang Liu, Lifu Wang, Wenjuan Yin, Alyssa Bouska, Qiang Gong +23 more

Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2378

N/A

0DataRank · unranked

43 citations

Anamarija M. Perry, Alex F. Herrera, Lu Chen, Pamela Skrabek, Michel R. Nasr +19 more

Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma

Leukemia(2020)10.1038/s41375-020-0739-7

N/A

0DataRank · unranked

10 citations

Caoimhe Egan, Alyssa Bouska, Weiwei Zhang, Qiang Gong, Girish Venkataraman +12 more